# Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers

> **NCT00913666** · PHASE4 · COMPLETED · sponsor: **Biogen** · enrollment: 121 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Interferon beta-1a (Avonex)

## Key facts

- **NCT ID:** NCT00913666
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** 2004-11
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2009-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00913666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00913666, "Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00913666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*